No Data
No Data
White House Office of Management and Budget Review on Cannabis-Derived Products Confirms Rapid Therapeutic Science Laboratories' Long-Term Strategy
Rapid Therapeutic Science Laboratories Updates Patents
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
Rapid Therapeutic Science Laboratories to Attend the Respiratory Drug Delivery (RDD) 2022 Conference
Rapid Therapeutics Science to begin trading on 1-for-25 reverse stock split adjusted basis
Rapid Therapeutic Science Laboratories Announces 1-for-25 Reverse Stock Split